Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeBionik LaboratoriesLandmark Robot Assisted Training for the RATULS Trial Completed

Landmark Robot Assisted Training for the RATULS Trial Completed

BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the completion of a landmark Robot Assisted Training for the Upper Limb after Stroke (RATULS) trial utilizing the Company’s InMotion Robotic Therapy Systems.

Results of the RATULS trial were presented at the European Stroke Organisation Conference (ESOC) in Milan, Italy on May 22, 2019 and published in the Lancet Online Journal on the same day. The study’s purpose was to compare clinical effectiveness of robot assisted training, enhanced upper limb therapy, and usual care for patients with moderate or severe upper limb functional limitation. The RATULS trial began in 2014 and was completed end of 2018.

“We are pleased that the RATULS trial confirmed the finding of previous research studies which demonstrated that robot-assisted therapy improved upper limb impairment when compared with conventional care methods for stroke victims. The trial’s finding that robotic therapy is the only therapy to statistically maintain a significant impairment advantage at six months after treatment is a strong signal that robotic therapy is critical for achieving positive patient outcomes,” said Dr. Eric Dusseux, CEO, BIONIK Laboratories. “BIONIK’s InMotion Robotic Therapy Systems have been selected for some of the largest interventional research studies over the past 10 years, including the Veterans Affairs Robotics Trial which confirmed robot-assisted therapy improvement in upper limb impairment using the Fugl-Meyer Assessment (FMA), a stroke-specific, performance-based impairment index. In the VA study, the impairment advantage achieved through robot-assisted therapy translated into significant upper limb function improvements using the Wolf Motor Function Test.”

For the RATULS trial, the primary outcome for upper limb success was determined by Action Research Arm Test (ARAT), with four distinct success criteria that varied according to baseline severity, not used previously and developed by the RATULS trial team. Although the findings demonstrated that robot-assisted therapy improved upper limb impairment, using this ARAT measurement, the trial was unable to conclude that robot-assisted therapy or enhanced upper limb therapy resulted in improved upper limb functionality after stroke compared with usual care provided to patients with stroke-related upper limb functional limitation. The attrition rate was also drastically reduced in patient population following either robotic therapy or enhanced upper limb therapy versus usual care only, and most of the withdrawals before 3 months in usual care were due to disappointment with treatment allocation.

BIONIK recognizes the difficulty of creating a level playing field for comparing technology-assisted therapy to conventional methods and commends Professor Helen Rogers and her UK research team for their diligent undertaking and extensive study of 770 patients over a four-year time period.

“We appreciate the ongoing medical study of innovative technology designed to improve patient recovery from stroke. We are also grateful for the extensive feedback provided by patients and clinical practitioners over the past three years as we have actively researched and developed improved capabilities for our robotic rehabilitation systems,” said Dr. Dusseux. “The combination of evidenced-based medicine and real-world clinical feedback have led to the release of substantially improved versions of the InMotion ARMTM Robotic Therapy System announced in early 2018, and the InMotion ARM/HANDTM Robotic Therapy System announced beginning of 2019. These versions of our products include enhanced software applications with patient-centric configurable protocols to assist the therapist in providing specialized treatment of stroke and traumatic brain injury. BIONIK looks forward to providing the most advanced solutions to allow clinicians to develop the appropriate rehabilitation methods to address upper limb impairment and reduced arm function. We have seen robotic therapy utilized effectively due to its inherent repeatability and predictability which facilitates the standardization of treatment protocols and consistent measurement of patient progress, another great way to reinforce the patient’s motivation.”

BIONIK’s InMotion Robotic Systems have now been utilized in two of the largest interventional trials completed for upper limb evaluation in the past 10 years. The Company’s robotic-assisted rehabilitation technologies were previously utilized in a trial led by the Providence Veteran Affairs Medical Center, involving 127 patients with moderate-to-severe upper-limb impairments six months or more after stroke. The results of that study were published in The New England Journal of Medicine in April of 2010.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy